0819 GMT - Danone's deal for a majority stake in U.S. plant-based nutrition company Kate Farms seems small, but strategic as it is aligned with the company's goal of bolstering its medical-nutrition operations, Barclays analysts say in a research note. "This is another clear sign of Danone's direction of travel as it bolsters Medical Nutrition, which we consider as Danone's best and fastest-growing business," the analysts say. The French food company didn't disclose the size of the stake nor the price. While the deal isn't material for Danone, it follows a similar path to the Functional Formularies deal, Barclays says, referring to the U.S. acquisition the company completed last year. Danone shares fall 2%. (adria.calatayud@wsj.com)
(END) Dow Jones Newswires
May 12, 2025 04:19 ET (08:19 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.